Integrating Omic Technologies in Alzheimer's Disease.
Scientific advances in biomedical disciplines have allowed us to identify the underlying causes of many diseases with increased comprehension-leading the way towards precision medicine. In this context, unique disease and medical traits pave the way for the development of adapted disease management, drugs and therapies tailored to each patient. Bearing in mind that reductionism, an approach that has dominated biomedical research for many years and has resulted in the identification of definite cellular phenotypes and human diseases which are linked with specific integral molecules, we strongly believe that Alzheimer's Disease, one of the most common neurodegenerative diseases, could not be applied to the model of one disease-one assay-one drug. Regarding the discrete complexities in the molecular pathogenesis combined with the limited knowledge of inherited and sporadic forms of Alzheimer's disease, the great heterogeneity in the clinical development, as well as the plethora of validated biomarkers that have been proposed for early diagnosis or prognosis of the disease, we presume that a radically different way of thinking is in demand for comprehensive explanations of the molecular pathogenesis of the disease. In this article we highlight the most recent advances made in the omics field of systems biology towards a more complete understanding of Alzheimer's disease mechanisms, emphasizing to the paramount emergence of the development of various high-throughput strategies applied to the omics sciences.